Alnylam Pharmaceuticals, Inc.

10-Q Quarter ended 2026-06-30 Jul 30, 2026 8-K Results of operations (earnings release) Jul 30, 2026 8-K Director or officer change; Shareholder vote results May 27, 2026 10-Q Quarter ended 2026-03-31 Apr 30, 2026 8-K Results of operations (earnings release) Apr 30, 2026 8-K Director or officer change Mar 4, 2026 10-K Fiscal year ended 2025-12-31 Feb 12, 2026 8-K Results of operations (earnings release) Feb 12, 2026 8-K Results of operations (earnings release) Jan 12, 2026 8-K Other events Dec 11, 2025 8-K Director or officer change Dec 3, 2025 10-Q Quarter ended 2025-09-30 Oct 30, 2025 8-K Results of operations (earnings release) Oct 30, 2025 8-K Entered a material agreement; Took on a direct financial obligation Oct 3, 2025 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity; Other events Sep 12, 2025 8-K Other events Sep 10, 2025 10-Q Quarter ended 2025-06-30 Jul 31, 2025 8-K Results of operations (earnings release) Jul 31, 2025 8-K Director or officer change Jun 18, 2025 8-K Amended charter or bylaws; Shareholder vote results May 13, 2025 10-Q Quarter ended 2025-03-31 May 1, 2025 8-K May 1, 2025 8-K Other events Mar 21, 2025 8-K Director or officer change Mar 5, 2025 10-K Fiscal year ended 2024-12-31 Feb 13, 2025 8-K Feb 13, 2025 8-K Results of operations (earnings release) Jan 13, 2025 10-Q Quarter ended 2024-09-30 Oct 31, 2024 8-K Oct 31, 2024 10-Q Quarter ended 2024-06-30 Aug 1, 2024 8-K Aug 1, 2024 8-K Shareholder vote results May 20, 2024 10-Q Quarter ended 2024-03-31 May 2, 2024 8-K May 2, 2024 8-K Director or officer change Mar 4, 2024 10-K Fiscal year ended 2023-12-31 Feb 15, 2024 8-K Results of operations (earnings release) Feb 15, 2024 8-K Director or officer change Jan 19, 2024 8-K Results of operations (earnings release) Jan 8, 2024 10-Q Quarter ended 2023-09-30 Nov 2, 2023